Resmed Inc: (NYSE: RMD)

$50.07

0.44 (0.89%)

Volume 472,740

May 17 04:05 PM ET

Zacks Rank: 3-Hold

 
 
#3
 
 

Company News

Get Company News for:

News For RMD

May 17, 2013 ResMed (RMD) Trading Near $50.59 Resistance Level - Freshbrewedmedia

May 15, 2013 ResMed Shares Sinking Lower, Down 1.2% - Financial News Network Online - Market Movers

May 14, 2013 ResMed: 52-Week High Recently Eclipsed (RMD) - Financial News Netwfork Online - 52-Week High-Lows

May 13, 2013 Shares of ResMed Rise to a New 52-Week High - Financial News Netwfork Online - 52-Week High-Lows

May 10, 2013 Recent 52-Week High Exceeded in Shares of ResMed (RMD) - Financial News Netwfork Online - 52-Week High-Lows

May 8, 2013 Shares of ResMed Have Risen Above Previous 52-Week High - Financial News Netwfork Online - 52-Week High-Lows

May 8, 2013 Stock Investors Bid Up Shares of ResMed, Up 2.4% - Financial News Network Online - Market Movers

May 8, 2013 Stocks Edge Up In Mixed Trade; DaVita Healthcare, Resmed Jump - Investors Business Daily

May 8, 2013 Stocks Extend Gains; Green Mountain Soars In After Hours - Investors Business Daily

May 8, 2013 Stocks Near Intraday Highs In Late Trade; Toyota Up - Investors Business Daily

May 7, 2013 DexCom has Relatively Underperformed its Peers in the Health Care Equipment Industry (DXCM, PODD, CYNO, HTWR, RMD) - Financial News Network Online - News Corner

May 7, 2013 ResMed Q3 net income increases - Datamonitor

Zacks Commentary For RMD

Apr 29, 2013 Zacks Blog: ResMed's Earnings Beat; Revs Lag

Apr 02, 2013 Zacks Blog: ResMed Protects Patent Landscape

Feb 22, 2013 Zacks Blog: Another Study for STJ's EnligHTN

Feb 22, 2013 Zacks Blog: Safeway Ticks Higher on 4Q Results

Feb 22, 2013 Zacks Blog: Symmetry Misses but Up Y-Y

Feb 20, 2013 Zacks Blog: Align Upgraded to Neutral

Feb 20, 2013 Zacks Blog: BioScrip Reaffirmed at Neutral

Feb 15, 2013 Zacks Blog: Qiagen in Collaboration with Lilly

Feb 15, 2013 Zacks Blog: Zimmer Stays at Neutral

Feb 14, 2013 Zacks Blog: The Zacks Analyst Blog Highlights: Cisco Systems, CVS Caremark, ResMed, Medical Action and MedAssets

Feb 13, 2013 Zacks Blog: Thermo Fisher Remains at Neutral

Feb 13, 2013 Zacks Blog: CVS Broadens Pharmacy Advisor

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.